Skin Conditions & Dermatology Clinical Trials Update: Week 19, 2026

Published May 8, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

This Phase 3 trial is exploring lebrikizumab, a new antibody treatment, for children and teens with moderate-to-severe atopic dermatitis, also known as eczema. If this treatment proves safe and effective, it may provide a new way to reduce the uncomfortable symptoms and improve quality of life for young patients living with this chronic skin condition. The study is enrolling children as young as six months up to 18 years old and will follow them for nearly two years, including an extension period.

An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

This trial is testing sonelokimab, an injectable drug, for adolescents aged 12 to 17 with moderate to severe hidradenitis suppurativa, a painful and recurring skin condition. The study focuses on the drug’s safety and how it behaves in the body. Successful results could offer a new treatment option that is better tolerated and more effective for young people managing this challenging disease. The trial is active but not currently recruiting and is mainly conducted in the United States.

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

This Phase 3 trial compares two oral medications, zasocitinib and deucravacitinib, in adults with moderate-to-severe plaque psoriasis. Both drugs aim to control symptoms such as red, scaly patches on the skin. If effective, these daily pills could provide convenient new options for adults seeking relief from this common form of psoriasis. Over 600 participants from multiple countries took part in this 16-week treatment study.

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

This early-stage trial is testing a new acne vaccine based on mRNA technology in adults aged 18 to 45 with moderate to severe acne. The vaccine works by targeting the immune system to reduce acne lesions and improve skin health. Recruiting in several countries including the United States, Australia, and Canada, this study plans to enroll 800 participants and could represent a novel approach to acne treatment if successful.

Effects of Non-Invasive Vagus Nerve Stimulation in Adolescent Burn Patients

This study examines whether non-invasive vagus nerve stimulation combined with physiotherapy can help adolescents ages 12 to 18 recover after burn injuries. The treatment aims to ease symptoms such as anxiety, pain, itching, and sleep problems that commonly follow burns. Conducted in Turkey, participants will receive 10 treatment sessions over two weeks with hopes of improving recovery and comfort after burns.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.